Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AQST | Aquestive Therapeutics, Inc.

Index- P/E- EPS (ttm)-0.45 Insider Own0.40% Shs Outstand61.73M Perf Week3.01%
Market Cap104.93M Forward P/E- EPS next Y-0.40 Insider Trans0.00% Shs Float57.87M Perf Month-3.39%
Income-22.60M PEG- EPS next Q-0.11 Inst Own29.60% Short Float / Ratio3.14% / 5.11 Perf Quarter-15.35%
Sales46.50M P/S2.26 EPS this Y39.70% Inst Trans-4.31% Short Interest1.82M Perf Half Y111.09%
Book/sh-1.86 P/B- EPS next Y-60.00% ROA-39.80% Target Price6.17 Perf Year48.70%
Cash/sh0.37 P/C4.68 EPS next 5Y- ROE20.50% 52W Range0.72 - 2.69 Perf YTD89.56%
Dividend- P/FCF10.93 EPS past 5Y-19.10% ROI63.30% 52W High-36.43% Beta2.62
Dividend %- Quick Ratio0.90 Sales past 5Y-6.60% Gross Margin54.20% 52W Low137.50% ATR0.12
Employees130 Current Ratio1.00 Sales Q/Q-0.80% Oper. Margin-61.80% RSI (14)52.24 Volatility7.11% 6.36%
OptionableYes Debt/Eq- EPS Q/Q71.80% Profit Margin-48.60% Rel Volume2.27 Prev Close1.53
ShortableYes LT Debt/Eq- EarningsAug 07 AMC Payout- Avg Volume356.13K Price1.71
Recom1.70 SMA203.57% SMA50-2.35% SMA20021.86% Volume808,311 Change11.76%
Date Action Analyst Rating Change Price Target Change
Apr-07-21Resumed RBC Capital Mkts Outperform $7
Apr-22-19Initiated H.C. Wainwright Buy
Jan-03-19Initiated Lake Street Buy $14
Aug-20-18Initiated RBC Capital Mkts Outperform $23
Aug-20-18Initiated JMP Securities Mkt Outperform $29
Sep-20-23 09:04AM
Sep-15-23 06:00PM
Sep-13-23 06:15PM
Sep-12-23 08:26AM
Sep-11-23 08:00AM
08:00AM Loading…
Aug-23-23 08:00AM
Aug-11-23 07:08AM
Aug-10-23 10:03AM
Aug-07-23 05:40PM
Aug-02-23 08:00AM
Jul-27-23 07:00AM
Jul-25-23 04:01PM
06:00PM Loading…
Jul-21-23 06:00PM
Jul-18-23 06:15PM
Jul-14-23 09:40AM
Jul-12-23 06:15PM
Jul-06-23 08:00AM
Jun-29-23 09:35AM
Jun-28-23 09:40AM
Jun-20-23 07:14PM
Jun-14-23 08:00AM
Jun-12-23 09:40AM
May-31-23 08:00AM
May-26-23 09:40AM
May-11-23 12:00PM
May-09-23 10:00AM
06:17AM Loading…
May-04-23 06:17AM
May-02-23 06:15PM
Apr-26-23 10:02AM
Apr-25-23 10:01AM
Apr-20-23 08:00AM
Apr-18-23 08:00AM
Apr-17-23 07:18AM
Mar-29-23 08:30AM
Mar-08-23 11:43PM
Mar-07-23 05:15PM
Mar-01-23 10:00AM
Feb-28-23 10:00AM
Feb-22-23 08:00AM
Feb-21-23 08:00AM
Feb-13-23 10:31AM
Jan-27-23 05:51AM
Jan-06-23 08:00AM
Dec-22-22 08:00AM
Nov-29-22 08:00AM
Nov-15-22 08:00AM
Nov-09-22 04:33PM
Nov-01-22 05:15PM
Oct-27-22 09:05AM
Oct-24-22 08:00AM
Oct-19-22 08:00AM
Oct-11-22 08:00AM
Sep-28-22 12:14PM
Sep-27-22 09:35AM
Sep-12-22 04:01PM
Aug-31-22 04:02PM
Aug-10-22 04:50PM
Aug-04-22 12:34PM
Aug-02-22 05:15PM
Jul-26-22 08:00AM
Jul-20-22 08:00AM
Jul-11-22 08:00AM
Jun-16-22 07:32AM
Jun-15-22 04:22PM
Jun-08-22 04:01PM
Jun-07-22 08:00AM
Jun-06-22 08:30AM
May-17-22 04:01PM
May-14-22 08:27AM
May-10-22 08:00AM
May-04-22 02:30PM
May-03-22 06:55PM
Apr-18-22 08:00AM
Apr-13-22 08:00AM
Apr-12-22 08:00AM
Mar-17-22 11:17AM
Mar-09-22 05:30PM
Mar-08-22 06:15PM
Mar-03-22 08:00AM
Mar-02-22 04:53AM
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.